Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability ...
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product ...
Patent reforms could address a problem that’s been driving rising prescription drug costs and create a more competitive ...
Dear reader, when we discuss the best-selling medications of all time, we’re exploring more than just products with massive ...
These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio ...
Everyday Health on MSN
Crohn’s Disease and Night Sweats: Why They Happen and How to Manage Them
Learn about the connection between Crohn’s disease and night sweats, their possible causes, and get practical tips from ...
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...
British Columbia's Human Rights Commissioner says the province is worsening the toxic drug crisis by treating substance use ...
As deadly drug overdoses climbed across Canada, decision-makers faced political backlash for funding programs that gave drug ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Alvotech ( ALVO) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Good day, and thank you for standing by. Welcome to the Alvotech Q3 2025 Earnings Conference Call. [Operator Instructions] Please ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback